Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY:LLY)

775.45 -19.67 (-2.47%)
Official Closing Price Updated: 7:00 PM EDT, Jun 27, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
FDA Halts Trials Exporting Americans' Cells To Hostile Countries For Genetic Engineering
FDA launches review of trials that sent American DNA to China without full consent; NIH investigates impact of Biden-era exemption on federally funded research 
Via Benzinga
Why Lilly's Bid for Verve Therapeutics Sent the Stock Soaring This Week
Via The Motley Fool
Stay informed with the top movers within the S&P500 index on Friday.
Curious about the S&P500 stocks that are in motion on Friday? Join us as we explore the top movers within the S&P500 index during today's session. 
Via Chartmill
Friday's session: gap up and gap down stock in the S&P500 index
Let's have a look at what is happening on the US markets on Friday. Below you can find the S&P500 gap up and gap down stocks in today's session. 
Via Chartmill
Looking At Eli Lilly's Recent Unusual Options Activity
Via Benzinga
Forecasting The Future: 7 Analyst Projections For Eli Lilly
Via Benzinga
McDonald’s Is Down, But Long-Term Investors Can Still Take a Bite
Analysts are downgrading McDonald's and the stock may have further to fall, but as a long-term opportunity, it may be getting to a point of offering real value 
Via MarketBeat
3 Unpopular Stocks Facing Headwinds
Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad things about a company because it can... 
Via StockStory
How IBD 50's Hims & Hers Is Shaking Up The Weight-Loss Brawl
This dark horse candidate has emerged to take significant share in the weight-loss drugs space. 
Via Investor's Business Daily
5 Growth Stocks to Invest $1,000 in Right Now
Via The Motley Fool
Topics Artificial Intelligence Economy World Trade
Q1 Earnings Outperformers: Eli Lilly (NYSE:LLY) And The Rest Of The Branded Pharmaceuticals Stocks
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q1. Today, we are looking at branded pharmaceuticals stocks, starting... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
Gilead Sciences Wins Approval For Highly Effective HIV Prevention Drug
The drug will sell under the brand name Yeztugo. In clinical testing, it kept 99.9% of patients from contracting HIV. 
Via Investor's Business Daily
Scholar Rock Stock Soars After Investigational Drug Helps Preserve Lean Mass: Retail Flags Lack Of Incremental Weight Loss
Apitegromab therapy with Tirzepatide preserved an additional 4.2 pounds of lean mass compared to Tirzepatide alone in the study, the company said. 
Via Stocktwits
Topics Death
Eli Lilly's $1.3 Billion Verve Deal Signals Confidence In Gene Editing Space: Analyst
Lilly's Verve acquisition lifts sentiment in gene editing stocks, with analysts calling it a strategic and timely move in a tough funding climate. 
Via Benzinga
Why Scholar Rock Shares Are Soaring Today
Via The Motley Fool
Topics Stocks
Scholar Rock's Atrophy Drug When Combined With Eli Lilly's Zepbound Shows Around 55% Better Muscle Preservation In Weight Loss Study
Scholar Rock's apitegromab helped preserve muscle mass during tirzepatide-induced weight loss, improving overall body composition in Phase 2 trial. 
Via Benzinga
Nobody Wants To Touch Healthcare Stocks Now – That Might Be A Big Mistake
Healthcare stocks are lagging the market by the widest margin since 2008. Analysts and valuation trends point to a rebound. 
Via Benzinga
Missed Out on Eli Lilly's 480% Gains Over the Past 5 Years? These GLP-1 Stocks Still Have Plenty of Upside.
Via The Motley Fool
Novo Nordisk Just Improved Its Weight-Management Pipeline: Is the Stock a Buy?
Via The Motley Fool
Topics Artificial Intelligence
Move Over Hims & Hers Health: This Insurance Business Could Be the Next Monster Healthcare Stock (Hint: It's Not UnitedHealth)
Hims & Hers Health shares rocketed higher over the last year, rewarding investors. 
Via The Motley Fool
Topics Government World Trade
Market Monitor News June 18 (Jabil, Reddit & Verve Therapeutics UP - Solar Stocks First Solar, Sunrun & SolarEdge DOWN)
Wall Street stays cool despite geopolitical tension, weak retail data, and a meltdown in solar stocks. 
Via Chartmill
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Verve Therapeutics, Inc. (Nasdaq - VERV), Sage Therapeutics, Inc. (Nasdaq - SAGE), Cantaloupe, Inc. (Nasdaq - CTLP), Volato Group, Inc. (NYSE American - SOAR)
From Brodsky & Smith LLC
Via GlobeNewswire
Why Verve Therapeutics Stock Is Skyrocketing Today
Via The Motley Fool
Surgery Partners Stock Slumps 13% After Company Rejects Bain Capital’s Take-Private Proposal
Chairman of the Independent Committee, Brent Turner, said the best path forward for Surgery Partners is to continue operating as an independent publicly traded company. 
Via Stocktwits
Members of Congress Are Pouring Millions Into These 7 Surprising Stocks
Via The Motley Fool
Verve Therapeutics Stock Rockets 75% Pre-Market After Eli Lilly Agrees To Acquire The Company For Up To $1.3B: Retail Says Offer Is ‘Low’
Lilly will acquire all outstanding shares of Verve for $10.50 per share in cash payable at closing, in addition to a contingent value right (CVR) per share that entitles holders to $3 per share,... 
Via Stocktwits
Verve Therapeutics Skyrockets — Pulling Gene-Editing Stocks Higher — On $1.3 Billion Eli Lilly Takeover
The companies were already collaborating on a handful of cardiovascular-focused gene-editing treatments. 
Via Investor's Business Daily
Eli Lilly Expands Into Gene Editing With Verve Therapeutics Acquisition
Eli Lilly is acquiring Verve Therapeutics to strengthen its cardiovascular pipeline with a gene-editing drug targeting PCSK9-linked conditions. 
Via Benzinga
May 2025 Industrial Manufacturing Near March 2025 Levels with 146 New Planned Capital Projects Heading into Summer
JACKSONVILLE, Fla., June 17, 2025 (SEND2PRESS NEWSWIRE) -- Industrial SalesLeads announced today the May 2025 results for its new planned capital project spending report for the Industrial... 
Via Send2Press
Verve Therapeutics Soars 75% After-Hours Following Report Of $1.3B Eli Lilly Takeover Talks
The deal would double Verve’s market value and expand Lilly’s pipeline of early-stage therapies. 
Via Stocktwits
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.